As one of the leading European service providers for the manufacturing, packaging and development of solid dosage forms, Rottendorf Pharma presents from May 2009 its new development and upscaling center. The pilot plant, built within one year, was inaugurated on May 6 in form of a symposium attended by international pharmaceutical experts.
On 2400 square metres the new premises, an investment of 9 million Euro, not only shows the common range of production technologies for solids but also offers innovative technologies such as melt extrusion, melt granulation and pellets. Rottendorf is therefore able to expand the existing service package and optimises its full service by generating new capacities for the formulation and process development, validation, manufacturing of small-scale, clinical and registration batches. Moreover, the service comprises analytical method development and validation, stability studies and support for registration issues.
Cooperation partner are among others Evonik Industries AG, Leistritz Extrusionstechnik GmbH and LifeCycle A/S, a danish company that developed the „MeltDose Technology“. All these new technologies enable Rottendorf to focus on process development for products with poorly soluble compounds and to intensify this exciting field of galenical development and production in collaboration with its customers and other partners.
The investment in the new pilot plant as a GMP and FDA compliant platform for new technological challenges is a guiding principle for Rottendorf. For Peter Verheyen and Dr. Stephan Fleck, Managing Director of the Rottendorf Group, the contract development plays a decisive role in the future company strategy. Due to a recent re-organization of the Rottendorf Group the Rottendorf Technologie GmbH, as independent company, may offer now new opportunities for co-operations in this sphere of activity.
On 2400 square metres the new premises, an investment of 9 million Euro, not only shows the common range of production technologies for solids but also offers innovative technologies such as melt extrusion, melt granulation and pellets. Rottendorf is therefore able to expand the existing service package and optimises its full service by generating new capacities for the formulation and process development, validation, manufacturing of small-scale, clinical and registration batches. Moreover, the service comprises analytical method development and validation, stability studies and support for registration issues.
Cooperation partner are among others Evonik Industries AG, Leistritz Extrusionstechnik GmbH and LifeCycle A/S, a danish company that developed the „MeltDose Technology“. All these new technologies enable Rottendorf to focus on process development for products with poorly soluble compounds and to intensify this exciting field of galenical development and production in collaboration with its customers and other partners.
The investment in the new pilot plant as a GMP and FDA compliant platform for new technological challenges is a guiding principle for Rottendorf. For Peter Verheyen and Dr. Stephan Fleck, Managing Director of the Rottendorf Group, the contract development plays a decisive role in the future company strategy. Due to a recent re-organization of the Rottendorf Group the Rottendorf Technologie GmbH, as independent company, may offer now new opportunities for co-operations in this sphere of activity.
